obesity drug news today glp-1 september 29 2025 There's lots going on this month at FDA in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Warning Letters Weight loss drugs like GLP-1s

Patient and public involvement This study investigated a well defined research question on a potential adverse event of GLP1 receptor agonists that is broadly recognised for its potential impact on patients, and that has been raised as a drug safety concern by drug regulatory agencies

But the biological plausibility is sound, and some clinicians are incorporating this strategy into their long-term GLP-1 treatment plans

Head-to-head trials (CONCLUDE and BRIGHT) showed comparable glucose control between the two, with some differences in hypoglycemia patterns depending on the trial design

Research has demonstrated that multiple immune cells are involved in the etiology and evolution of RA, including macrophages, monocytes, neutrophils, and T cells [231]

However, a long-term exploratory RCT in 150 people with obesity found that differences in eating disorders psychopathology scores were not maintained at 52 weeks when liraglutide in combination with behavioral therapy was compared with behavioral therapy alone 215